問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Cancer Center

Division of Nuclear Medicine

Division of Hematology & Oncology

National Taiwan University Hospital

Division of Nuclear Medicine

更新時間：2025-10-18

莊佩儒
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

5Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

莊佩儒

List

7Cases

2024-09-15 - 2029-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2029-12-31

Phase I/II

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
2Sites

Recruiting2Sites

2025-12-01 - 2029-06-30

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2024-10-01 - 2035-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2023-06-03 - 2030-04-29

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2025-02-03 - 2033-05-03

Phase II/III

Active
一項第 II/III 期、開放性、跨國、多中心、隨機分配試驗，在 [177Lu]Lu-PSMA 精準放射標靶療法期間或之後惡化的 PSMA 陽性轉移性去勢抗性前列腺癌成人參與者中，比較 AAA817 相較於標準照護的治療

  • Condition/Disease

    PSMA-positive metastatic castration-resistant prostate cancer

  • Test Drug

    AAA817

Participate Sites
4Sites

Recruiting4Sites

2025-05-01 - 2028-02-29

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB